Galectin Therapeutics Inc. (GALT)

[Tesla1]

Chess: Based on cohort 1 and reading the animal studies, I think that the 2nd cohort will be a homerun but there is still value in completing the 3rd cohort. The 3rd cohort in my opinion will prove to be completely curative and the company could then file for "breakthrough" designation. Breakthrough designation, I believe, would allow for FDA approval after phase 2 has been completed. It could mean approval for GRMD02 by 2016 (which is years before the market expects approval). That would be the type of catalyst which would propel the valuation up and up. My opinion is that OCA and GRMD02 are going to end up being combination treatments for NASH. GRMD02 could be added to treatment when patients have stage 3 or 4 fibrosis. That is a huge unmet patient population. ALL IMO.